Kathy Hughes

Kathy Hughes advises Avalere clients on value strategies, market access, and evidence planning.

Kathy partners with life sciences companies to scrutinize complex issues in market access, craft strategies and tactics to address them, and plan for and perform the analytics necessary for their success.

Prior to joining Avalere, Kathy was co-leader of the Market Access practice at Covance and the chief operating officer at Holy Cross Health Corp. She has served as vice president for Corporate and Strategic Planning for Blue Shield of California and senior manager with Ernst and Young’s Healthcare Management consulting practice.

Kathy has an MBA from the University of Chicago and a BA from Brandeis University. She also has a Certificate of Completion from the Mid-Atlantic Health Leadership Institute at The Johns Hopkins Bloomberg School of Public Health and is a senior fellow at the Thomas Jefferson University School of Population Health.

Authored Content

Avalere experts published a supplement in the June 2019 American Journal of Managed Care entitled “Ensuring Appropriate Access to Pulmonary Arterial Hypertension Therapy.”

Outcomes-based contracts most common in cardiovascular disease, infectious disease, and oncology.

Of the 329 oncology HTAs analyzed from the period 2013–2017, 29% resulted in positive recommendations without restrictions.

Market access teams should consider 3 growing trends in their 2018 strategic planning.

Avalere experts examine the challenges and successful approaches to outcomes-based contracts.

Shifting to a value-based purchasing (VBP) system provides opportunities to engage payer and provider customers in unique contracting and reimbursement relationships that may optimize market access.

Avalere hosts a series of webinars on “Navigating the New Dynamics of Outcomes Contracting and Risk Sharing Arrangements”. While traditional rebating and discounting terms have been a staple of industry contract negotiations, a new strategic focus is emerging on additional modes through which overall value can be measured for the wave of high-cost drugs now coming to shore.

Meet Kathy Hughes who leads our Molecular Diagnostics team and has successfully advised device, diagnostics and pharmaceutical companies on optimal market access strategies for over a decade. Kathy addresses key evidentiary developments in the diagnostics space, and what she sees as the future of this evolving field.

Avalere will be hosting a conference on the future of market access for diagnostics and personalized medicine.

With over 16,000 genetic tests already on the market and thousands more in development, stakeholders cannot ignore the rapidly evolving field of personalized medicine.

Many of Avalere's experts are heading north to Canada for ISPOR's 19th Annual International Meeting, where we'll have several panel discussions and poster presentations.